Development status and competition pattern of peripheral artery interventional medical device market in China

In the field of lower limb arterial stents, China’s domestic market is basically occupied by international giants such as Medtronic, Boston Science, Cordis, BD, Abbott and so on, lack of strong competitors. Local companies in the R&D stage include Leao Medical, Guichuang Tongqiao, Yinluo Medical, Life Care, etc. Among them, Le Ao Medical announced in March 2021 that its randomized controlled clinical trial of peripheral arterial stents were completed ,and all 384 were enrolled in the group , becoming the first local peripheral arterial stent to complete clinical enrollment, and according to the data that completed clinical follow-up, the long-term patency rate of the peripheral arterial stent of Leao Medical is similar to that of the imported control product, and some of the evaluation indicators are even better than imported products, it is expected to break the monopoly pattern of imported arterial stents in one fell swoop after being listed in the future.

According to the data from Frost & Sullivan , the number of peripheral arterial interventional operation in China in 2017 reached to 99,400 cases. At present, it is in the early stage of development in China and is expected to increase continuously with the improvement of living standards and health awareness in the future,and will increase to 170,798 cases in 2022, with a compound growth rate of 11.4% during the period. In peripheral arterial interventional therapy ,the amount of lower extremity arterial interventional operations accounted for about 72.8% of the total peripheral arterial interventional operations, and the growth rate is the fastest, with a compound growth rate of 13.4% from 2017 to 2022. It is expected that lower extremity arterial interventions operations will reach to 119,000 cases in 2021.

In 2017, the market for peripheral vascular interventional devices in China is about 3.01 billion yuan (including 2.12 billion yuan for peripheral artery intervention and 890 million yuan for intravenous intervention). The market is expected to reach about 7.12 billion yuan by 2022, with an average annual compound growth rate of about 18.8%.

Please do not hesitate to contact us at info@ inspirativemed.com if you have any interest in bringing medical device into China.